Derek Lowe
An Arkansan by birth, Derek got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He’s worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer’s, diabetes, osteoporosis and other diseases.
Derek writes the popular blog In the pipeline on drug discovery and the pharma industry.
OpinionWhy combination pills aren’t always the answer
The challenges of medicines containing multiple drugs aren’t going away
OpinionWill robots make you redundant?
Smart machines could soon outpace even the best organic chemist
OpinionWhy modern chemists need to think big
The lessons we can learn from the larger reaction scales of the past
OpinionFor the sake of argument
It’s important to recognise which disputes can actually be resolved by science
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry
OpinionAn opportunity ignored
Dismissing ideas that were ‘not invented here’ is like walking past a $100 bill
OpinionMake room for randomness in drug development
Setting free the dark horses sometimes beats the most rational planning
OpinionMaking enough of a difference
What if the needle in the drug development haystack ends up being too small to be useful?
OpinionUnpicking a clinical trial death
A new study shows up off-target effects of a drug that proved deadly, and highlights the pitfalls of drug discovery
OpinionHow safe should drugs be?
What does spotting new risks in approved medicines say about how effective regulators are?
OpinionAlternate chemical realities
What would chemistry look like if key discoveries had happened differently?
OpinionHow does being a chemist change your view on the world?
Scientific knowledge and analysis shape our view, but can also be selectively ignored
OpinionOutlines of ignorance
There’s a lot about chemistry that we just don’t understand very well yet
OpinionDrug regulation is a burden worth bearing
Calls to break down regulatory barriers show a misunderstanding of the industry
OpinionHow much does fashion influence chemists?
Is that new reaction the next Nobel-worthy breakthrough, or just a flash in the pan?
CareersThe trials and tribulations of drug discovery
The many pitfalls medicinal chemists face when creating a new drug
OpinionPutting chemistry back in biology
The chemical nature of biomolecular interactions can no longer be ignored
